INVESTMENT YEAR: 2013
Advanced BioDesign (ABD) is developing a new drug for the treatment of cancers resistant to current therapies. The mechanism of action of this synthetic compound constitutes a technological breakthrough in the means of treating cancer
ABD, having acquired a unique expertise in the field of cancer, is developing a new cancer treatment therapy. This program, known as SEFALDIN, has proven that it is possible to achieve targeted destruction of cancer cells by restoring the mechanisms for apoptosis that they have escaped by becoming malignant. The originality of the synthetic compound developed by ABD(Dimate) resides in its action on the detoxification mechanisms present in cancer cells.
The first cancer model chosen for this project is acute myeloid leukemia (AML), one of the most challenging cancers. In vitro studies have also validated Dimate’s therapeutic efficacy on aggressive solid tumor models (more than 230 to date) and particularly on resistant lines such as triple negative breast cancer and lung cancer.
Proof of concept has been extended in animal models for AML, melanoma and lung cancer and is in the process of validation for lymphoma, osteosarcoma, breast, pancreatic and colon cancer models.
Mouse with lung cancer without treatment
Mouse after 24 days of treatment with Dimate